North China Pharmaceutical's (SHA:600812) eight products won preliminary bids under China's drug procurement program, according to a Tuesday disclosure to the Shanghai Stock Exchange.
Two of the drugs, cyclosporine and tacrolimus capsules, are indicated for transplant patients, while edoxaban tosilate is an anticoagulant.
The other five products, teicoplanin, vancomycin hydrochloride, isavuconazonium sulfate, ceftazidime and avibactam sodium, and imipenem and cilastatin sodium, are all antibiotic injections.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments